Bahl & Gaynor Inc. Has $4.44 Million Stake in Innospec Inc. (NASDAQ:IOSP)

Bahl & Gaynor Inc. boosted its stake in Innospec Inc. (NASDAQ:IOSP) by 3.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,001 shares of the specialty chemicals company’s stock after buying an additional 1,177 shares during the quarter. Bahl & Gaynor Inc. owned approximately 0.14% of Innospec worth $4,437,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Innospec by 0.4% in the third quarter. Vanguard Group Inc. now owns 2,941,356 shares of the specialty chemicals company’s stock worth $300,607,000 after purchasing an additional 11,502 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Innospec by 4.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 298,635 shares of the specialty chemicals company’s stock worth $30,520,000 after purchasing an additional 12,135 shares in the last quarter. Sei Investments Co. boosted its stake in Innospec by 8.7% in the third quarter. Sei Investments Co. now owns 128,506 shares of the specialty chemicals company’s stock worth $13,133,000 after purchasing an additional 10,268 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Innospec by 19.7% in the third quarter. Acadian Asset Management LLC now owns 111,652 shares of the specialty chemicals company’s stock worth $11,393,000 after purchasing an additional 18,371 shares in the last quarter. Finally, Raymond James & Associates boosted its stake in Innospec by 5.2% in the third quarter. Raymond James & Associates now owns 90,149 shares of the specialty chemicals company’s stock worth $9,213,000 after purchasing an additional 4,460 shares in the last quarter. Institutional investors and hedge funds own 96.64% of the company’s stock.

Insider Activity

In other news, Director Leslie J. Parrette purchased 410 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average price of $123.96 per share, with a total value of $50,823.60. Following the completion of the purchase, the director now directly owns 3,620 shares of the company’s stock, valued at approximately $448,735.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP David B. Jones sold 2,500 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $125.79, for a total transaction of $314,475.00. Following the completion of the transaction, the senior vice president now directly owns 9,664 shares of the company’s stock, valued at $1,215,634.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Leslie J. Parrette purchased 410 shares of Innospec stock in a transaction that occurred on Thursday, February 22nd. The shares were bought at an average cost of $123.96 per share, with a total value of $50,823.60. Following the completion of the transaction, the director now directly owns 3,620 shares of the company’s stock, valued at approximately $448,735.20. The disclosure for this purchase can be found here. Insiders have sold 36,500 shares of company stock valued at $4,532,959 over the last 90 days. 1.52% of the stock is owned by company insiders.

Innospec Stock Performance

Innospec stock opened at $121.12 on Friday. The firm has a market cap of $3.02 billion, a P/E ratio of 21.75 and a beta of 1.10. The business’s fifty day moving average is $124.28 and its two-hundred day moving average is $115.90. Innospec Inc. has a 52 week low of $91.74 and a 52 week high of $131.18.

Innospec (NASDAQ:IOSP) last posted its quarterly earnings data on Tuesday, February 13th. The specialty chemicals company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.59 by $0.25. Innospec had a return on equity of 13.69% and a net margin of 7.14%. The company had revenue of $494.70 million for the quarter, compared to analyst estimates of $479.47 million. During the same quarter in the previous year, the firm earned $1.20 earnings per share. The business’s revenue was down 3.1% on a year-over-year basis. On average, equities research analysts predict that Innospec Inc. will post 6.77 earnings per share for the current year.

Innospec Profile

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.